Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATICПодробнее

Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATIC

New Standard of care Treatment for EGFR Exon 20 Non-small cell Lung Cancer | Dr. Alexander SpiraПодробнее

New Standard of care Treatment for EGFR Exon 20 Non-small cell Lung Cancer | Dr. Alexander Spira

Second line treatment in activating EGFR non-small cell lung cancer, MARIPOSA - 2 | Onc BrothersПодробнее

Second line treatment in activating EGFR non-small cell lung cancer, MARIPOSA - 2 | Onc Brothers

First line treatment options for activating EGFR non-small cell lung Cancer | Dr. Alexander SpiraПодробнее

First line treatment options for activating EGFR non-small cell lung Cancer | Dr. Alexander Spira

ESMO 2023 Lung Cancer - Chapter 2 Highlights – PAPILLON, MARIPOSA, MARIPOSA-2, LIBRETTO-431Подробнее

ESMO 2023 Lung Cancer - Chapter 2 Highlights – PAPILLON, MARIPOSA, MARIPOSA-2, LIBRETTO-431

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinibПодробнее

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib